menu
    • menu
    [{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Panitumumab","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABP 234","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABP 234","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Zai Lab"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Xaluritamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABP 206","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABP 206","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Five Prime Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Five Prime Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acapatamab","moa":"FOLH1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Xaluritamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Xaluritamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AMG330","moa":"CD33\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Merck & Co"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AMG701","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"FPA144","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":2.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":2.5,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":2.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":2.5,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Medilink","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"YL201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Medilink","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Medilink"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG509","moa":"STEAP1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG256","moa":"GFRAL","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AMG994","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AMG160","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AMG794","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMG305","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMG355","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Carmot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AMG193","moa":"MAT2A","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lomustine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Qiagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMG193","moa":"MAT2A","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AMG193","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Revolution Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||PTPN11","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Sovilnesib","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Volastra Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Volastra Therapeutics"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG650","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AMG193","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Amgen Inc","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Plexium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amgen Inc","amount2":0.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Arrakis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Amgen Inc","amount2":1.25,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.25,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"PostEra","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Oncology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0.41999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Parexel"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AmMax Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 820","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ AmMax Bio","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ AmMax Bio"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"CytomX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CX-904","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ancora Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TNB-486","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Ancora Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Ancora Biotech"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MP0310","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Kite Pharma"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG910","moa":"CD3\/CEA","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AMG340","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AMG176","moa":"BCL-XL","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AMG193","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-486","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"MediLink Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Tarlatamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AMG 410","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Asher Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Xaluritamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Amgen Inc

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xaluritamig

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xaluritamig + AR Pathway Inhibitors Safety & Efficacy in Hormone-sensitive Prostate Cancer

                            Details : Xaluritamig is a Protein drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Prostatic Neoplasms, Castration-Sensitive.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : Xaluritamig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Tarlatamab for People with Prostate Cancer

                            Details : Tarlatamab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 08, 2025

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMG 410

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of AMG 410 Alone or with Other Agent in KRAS-Altered Advanced/Metastatic Solid Tumor

                            Details : AMG 410 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 30, 2025

                            Lead Product(s) : AMG 410

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Grupo Espanol de Tumores Neuroendocrinos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Refractory Advanced diGestive Neuroendocrine Carcinomas Treated with tARlatamab

                            Details : Tarlatamab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Digestive System Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 11, 2025

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Grupo Espanol de Tumores Neuroendocrinos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Institut Cancerologie de l'Ouest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-label Non-randomized Multicentric Phase 2 Study Evaluating the Combination of Bemarituzumab + FLOT Chemot...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 13, 2025

                            Lead Product(s) : Bemarituzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Institut Cancerologie de l'Ouest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YL201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Medilink

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Partic...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            March 27, 2025

                            Lead Product(s) : YL201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Medilink

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 10, 2025

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : University of Arizona

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 07, 2025

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : University of Arizona

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Jonsson Comprehensive Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Jonsson Comprehensive Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of How Safe and Effective Tarlatamab is in Brain Cancers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 15, 2025

                            Lead Product(s) : Tarlatamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth